Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
Open Access
- 1 February 2016
- journal article
- review article
- Published by SciELO Agencia Nacional de Investigacion y Desarrollo (ANID) in Revista médica de Chile
- Vol. 144 (2) , 232-240
Abstract
Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjögren's syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.Keywords
This publication has 39 references indexed in Scilit:
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology, 2015
- State of the art: Reproduction and pregnancy in rheumatic diseasesAutoimmunity Reviews, 2015
- Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literatureJournal of the American Academy of Dermatology, 2015
- Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndromeAutoimmunity Reviews, 2015
- Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal AssociationsAmerican Journal of Clinical Dermatology, 2013
- Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive PatientsCurrent Rheumatology Reports, 2010
- Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndromeRheumatology International, 2010
- Triple therapy in early active rheumatoid arthritis: A randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategiesArthritis & Rheumatism, 2008
- Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrualArthritis & Rheumatism, 2005
- The use of quinacrine (Atabrine) in rheumatic diseases: A reexaminationSeminars in Arthritis and Rheumatism, 1989